Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% above 2 million yuan [2] - The age distribution of CFOs shows that 54% are aged between 40 and 50, 35% are over 50, and 11% are 40 or younger, with the youngest being 30 years old and the oldest being 65 years old [1] Group 2 - The top three highest-paid CFOs in the medical device sector are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] - The CFO with the largest salary decrease in 2024 is Zhang Qiu from Kangtong Medical, with a year-on-year decrease of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2] - The educational background of CFOs shows that 71% hold a bachelor's degree, 23% a master's degree, and only 3% hold a doctoral degree, with only one CFO having a PhD [1]

医疗器械 ETF（562600）为投资者提供一键把握医疗器械行业成长机遇的便捷工具。该ETF追踪的中证 全指医疗器械指数，精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上 市公司证券作为样本。按wind脑机接口指数测算，截至2025年8月6日指数含脑机接口权重21.9%，从行 业结构看，该指数医疗器械行业占比高达 89.08%，集中度突出，能精准捕捉医疗器械领域的发展红 利。感兴趣的投资者可以持续关注。 （文章来源：每日经济新闻） 提出到2027年、2030年两步走发展目标，明确五大重点任务，细化17项具体举措，进一步推动脑机接口 产业高质量发展。这一重磅文件的出台，为我国脑机接口产业的未来发展描绘了清晰的蓝图，有望在全 球科技竞争中抢占先机，培育出具有国际竞争力的未来产业新赛道。 受此影响，医疗器械板块持续活跃，医疗器械ETF短暂调整后直线拉升，发稿时涨超1%。持仓股票赛 诺医疗20厘米涨停，利德曼、麦澜德、尚荣医疗、美好医疗涨幅居前。 消息面，工业和信息化部、国家发展改革委等7 部门发布关于推动脑机接口产业创新发展的实施意见。 ...

Group 1 - The assisted reproductive industry is experiencing a rebound, with significant stock price increases for several companies [1] - Lideman's stock rose over 18%, indicating strong market interest and potential recovery in the sector [1] - Other companies such as Nanmo Bio, Mailande, and Guangshengtang also saw notable gains, with increases of over 15%, 14%, and additional follow-up gains from other firms [1]

Group 1 - The core viewpoint of the news is the significant advancements expected in brain-computer interface (BCI) technology by 2027, with the establishment of an advanced technical, industrial, and standard system [1][3] - The Ministry of Industry and Information Technology, along with six other departments, has issued implementation opinions to promote innovation and development in the BCI industry, aiming for breakthroughs in key technologies and the establishment of a robust industrial ecosystem by 2030 [3] - The BCI market is projected to expand rapidly, driven by the increasing application of BCI products in various sectors such as industrial manufacturing, healthcare, and consumer life [3][4] Group 2 - Following positive news, several BCI-related stocks experienced significant price increases, with Beiyikang reaching a 13.57% rise and Sanbo Brain Science increasing by 11.69% [2] - The report from Founder Securities highlights the acceleration of commercial transformation in the BCI sector, particularly in non-invasive applications for medical rehabilitation and emotional management, indicating a broad market outlook [4] - Open Source Securities notes that the BCI technology landscape is undergoing rapid transformation, with upstream technological advancements leading to breakthroughs in downstream applications, suggesting a promising commercial future for domestic BCI companies [4]

Core Viewpoint - The company has approved the use of up to RMB 52,600 million of temporarily idle raised funds for cash management, ensuring that this does not affect the implementation of fundraising investment projects and is in the interest of all shareholders [3][22]. Group 1: Meeting Details - The second meeting of the supervisory board was convened on July 25, 2025, via communication, with all three supervisors present, complying with relevant laws and regulations [2]. - The meeting's resolutions were deemed legal and effective [2]. Group 2: Fund Management Proposal - The supervisory board approved the proposal to use up to RMB 52,600 million of temporarily idle raised funds for cash management, which aligns with regulatory requirements and does not conflict with the intended use of the raised funds [3][22]. - The funds will be invested in low-risk, high-liquidity products such as structured deposits, large certificates of deposit, and time deposits, with a usage period of 12 months from the approval date [7][11]. Group 3: Fundraising Overview - The company raised a total of RMB 100,725 million through its initial public offering, with a net amount of RMB 90,975.85 million after deducting issuance costs [7][8]. - All raised funds are stored in a dedicated account, and the company has established a three-party supervision agreement with the underwriter and the bank [8]. Group 4: Investment Purpose and Benefits - The purpose of using idle funds for cash management is to enhance fund utilization efficiency and increase returns while ensuring the safety of the raised funds [10]. - This strategy is expected to improve overall performance and provide better returns for shareholders [17]. Group 5: Approval and Oversight - The proposal received unanimous approval from the supervisory board, confirming that it complies with relevant regulations and does not harm shareholder interests [22][23]. - The underwriter has also expressed no objections to the cash management plan, affirming that it will not affect the company's main business operations [24].

Group 1 - The company held its 12th meeting of the second Supervisory Board on July 25, 2025, via communication, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to use up to RMB 526 million of temporarily idle raised funds for cash management, stating that this decision aligns with regulatory requirements and does not conflict with the implementation of investment projects [1][2] - The decision to manage idle funds is expected to enhance the company's capital efficiency and yield good financial returns, with unanimous support from all supervisors [1]

南京证券股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为麦澜 德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规和规范性文件 的要求，对麦澜德使用部分暂时闲置募集资金进行现金管理的事项进行了认真、 审慎的核查，核查情况如下： 一、本次募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同 意南京麦澜德医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可 〔2022〕1189 号），公司获准向社会公众公开发行人民币普通股（A 股）2,500 万 股，每股面值为人民币 1 元，每股发行价格为人民币 40.29 元，募集资金总额为人 民币 100,725.00 万元，扣除各项发行费用人民币 9,749.15 万元（不含增值税）后， 实际募集资金净额为人民币 90,975.85 万元 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688273 证券简称：麦澜德 公告编号：2025-026 南京麦澜德医疗科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 | 序号 | 项目名称 | 项目总投资额 （万元） | 拟投入募集资金额 （万元） | 自有资金投入 （万元） | | --- | --- | --- | --- | --- | | 1 | 麦澜德总部生产基地建 设项目 | 38,505.80 | 36,919.00 | 1,586.80 | | 2 | 研发中心建设项目 | 21,203.07 | 15,167.33 | 6,035.74 | | 3 | 营销服务及信息化建设 项目 | 5,291.61 | 5,291.61 | 0.00 | | | 合计 | 65,000.48 | 57,377.94 | 7,622.54 | 截至 2024 年 12 月 31 日，公司募投项目及募集资金使用情况具体详见公司于 2025 年 4 月 24 日披露于上海证券交易所网站（www ...

二、监事会会议审议情况 经与会监事审议表决，形成会议决议如下： （一）审议通过《关于使用部分暂时闲置募集资金进行现金管理的议案》 经审议，监事会认为：公司本次使用不超过人民币 52,600.00 万元（含）的部 分暂时闲置募集资金进行现金管理，内容及审议程序符合《上市公司募集资金监 管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规、规范性文件和公司《募集资金管理制度》的相关规定，且公司本次 使用部分暂时闲置募集资金进行现金管理没有与募集资金投资项目的建设内容相 抵触，不影响募集资金投资项目的正常实施，不存在变相改变募集资金投向和损 害公司股东利益特别是中小股东利益的情形，符合公司和全体股东的利益，有利 于提高公司的资金使用效率，获取良好的资金回报。全体监事一致同意公司使用 额度不超过人民币 52,600.00 万元（含）的部分暂时闲置募集资金进行现金管理。 证券代码：688273 证券简称：麦澜德 公告编号：2025-025 南京麦澜德医疗科技股份有限公司 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

Core Viewpoint - The postpartum care and recovery market in China is experiencing significant growth, driven by increasing consumer spending and awareness of health and wellness among modern women, with the market expected to exceed 200 billion yuan by 2030 [1][20]. Group 1: Industry Overview - Postpartum care and recovery refers to the recovery and maintenance that women require after childbirth due to physical weakness, which is gaining attention as women invest more in their health and wellness [1][2]. - The market size for postpartum care and recovery in China is projected to reach 67.5 billion yuan in 2024, representing a year-on-year growth of 13.6%, with postpartum recovery and care markets at 22.7 billion yuan and 44.8 billion yuan respectively [1][8]. Group 2: Market Segmentation - Postpartum care services can be categorized into confinement centers and postpartum doulas, with confinement centers gaining popularity due to their professional services and management, leading to a market size increase from 11.3 billion yuan in 2020 to 29.6 billion yuan in 2024, a compound annual growth rate of 27.2% [1][10][12]. - The postpartum doula market is also growing, with a projected market size of 15.1 billion yuan in 2024, reflecting a year-on-year growth of 4.1% [1][16]. Group 3: Consumer Trends - The increasing living standards and changing consumption concepts are driving more families to hire postpartum doulas for maternal and newborn care, while the rising wages of doulas due to supply-demand imbalances are further expanding the market [1][16]. - The consumer spending on healthcare has risen significantly, with per capita healthcare expenditure increasing from 1,165 yuan in 2015 to 2,547 yuan in 2024, indicating a growing willingness to invest in postpartum care [1][6]. Group 4: Competitive Landscape - The postpartum care and recovery market in China is highly fragmented, with approximately 6,300 confinement centers and 2,600 postpartum doula service providers, leading to intense competition [1][18]. - The top five companies in the industry hold only 3.7% of the market share, indicating a diverse range of players, with brands like Saint Bella and Aidi Palace being well-known [1][18]. Group 5: Future Trends - The industry is expected to continue expanding, with a forecasted market size exceeding 200 billion yuan by 2030, driven by increased awareness of postpartum recovery among women [1][20]. - The industry is moving towards standardization and regulation, with ongoing efforts to improve oversight and quality standards [1][21]. - There is a trend towards more diverse and professional services, with companies enhancing employee training and exploring varied service offerings to meet consumer demands [1][23]. - The industry is also accelerating its digital transformation, utilizing information technology to improve service efficiency and quality [1][24].